The Zacks Analyst Blog Highlights: Health Care Select Sector SPDR ETF, SPDR S&P 500, SPDR S&P Health Care Services ETF, iShares U.S. Healthcare Providers ETF and Guggenheim S&P 500 Equal Weight Health Care ETF - KFDA - NewsChannel 10 / Amarillo News, Weather, Sports

The Zacks Analyst Blog Highlights: Health Care Select Sector SPDR ETF, SPDR S&P 500, SPDR S&P Health Care Services ETF, iShares U.S. Healthcare Providers ETF and Guggenheim S&P 500 Equal Weight Health Care ETF

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact

SOURCE Zacks Investment Research, Inc.

CHICAGO, Aug. 8, 2014 /PRNewswire/ -- announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Health Care Select Sector SPDR ETF (AMEX:XLV-Free Report), SPDR S&P 500(AMEX:SPY-Free Report), SPDR S&P Health Care Services ETF (AMEX:XHS-Free Report), iShares U.S. Healthcare Providers ETF (AMEX:IHF-Free Report) and Guggenheim S&P 500 Equal Weight Health Care ETF (AMEX:RYH-Free Report).

Zacks Investment Research, Inc.,

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Thursday's Analyst Blog:

Healthcare ETFs Leading the Pack


The Q2 earnings season has been impressive with both earnings and revenue growth rates exceeding expectations and outpacing the numbers in the past few quarters. Total earnings for the S&P 500 companies that have reported results so far are up 9% with a beat ratio of 65.6%, while revenues are up 4.6% with a revenue beat ratio of 60.6%.

Companies across a wide number of sectors have posted strong results beating analyst estimates. The estimate revision trend for Q3 is also not as bad as was seen in the previous quarters. In fact, the magnitude of Q3 negative revisions is the lowest in more than a year, suggesting modest improvement on the guidance front (read: 4 Ways to Play Earnings Growth with ETFs).

While there have been winners in many corners generating double-digit growth, the medical sector is clearly leading the way. This is especially true as the sector has been the major contributor to both earnings (+15.8%) and revenue (+12.4%) growth so far, crushing estimates and providing a solid outlook.

Earnings growth has more than doubled that of Q1 thanks to encouraging industry trends. Increased merger and acquisition activities, development of new drugs, expansion into emerging markets, ever-increasing health care spending, an aging population and the Affordable Care Act (often known as Obamacare) are fueling growth in the space.

In particular, earnings at Gilead Sciences, Amgen,  Pfizer and Merck have been inspiring, thereby becoming yardsticks for other stocks in the space. The stock prices have also been surging since their earnings release (read: Pharma ETFs in Focus on String of Earnings Beat).

Further, the healthcare sector actually has the best Rank for any industry at the time of writing – about 70% of the industries under healthcare have Zacks Ranks in the top 42%, spreading optimism in the sector.

Healthcare ETFs in Focus

Resultantly, a number of healthcare ETFs have provided handsome returns buoyed by solid earnings growth. However, the gains have been badly eroded by renewed geopolitical tensions and a stumbling stock market last week.

However, we have highlighted three funds that are still outpacing the broad sector (AMEX:XLV-Free Report) and the broad market (AMEX:SPY-Free Report) funds by wide margins. These products currently have a Zacks ETF Rank of 3 or 'Hold' rating.

SPDR S&P Health Care Services ETF (AMEX:XHS-Free Report)

This fund uses equal weight methodology to each security by tracking the S&P Health Care Services Select Industry Index. Holding 55 stocks in its basket with AUM of $86.8 million, each security accounts for less than 2.5% of total assets. The ETF is skewed toward small caps at 56% while large and mid-caps account for 23% and 21% share, respectively (read: Guide to Small Cap Growth ETFs Investing).


From a sector look, healthcare services and healthcare facilities take the top two spots with 35.1% and 29.3% share, respectively. The fund charges 35 bps in fees per year from investors and trades in a paltry volume of around 5,000 shares a day. The ETF added 0.20% in the trailing one-month period.


iShares U.S. Healthcare Providers ETF (AMEX:IHF-Free Report)

This ETF follows the Dow Jones U.S. Select Healthcare Providers Index with exposure to companies that provide health insurance, diagnostics and specialized treatment. In total, the fund holds 48 securities in its basket with the largest allocation going to United Health and Express Scripts at 12.8% and 9.8%, respectively. Other firms do not hold more than 6.7% of IHF.


The product has a certain tilt toward large caps, as these account for 54% share while the rest is roughly spilt between mid and small caps. The fund has been able to manage $542.7 million in its asset base while volume is light under 6,000 shares per day on average. It charges 43 bps in annual fees and expenses. The ETF lost 0.17% over the past month (see: all the Healthcare ETFs here).


Guggenheim S&P 500 Equal Weight Health Care ETF (AMEX:RYH-Free Report)

This fund also provides equal weight exposure of around 2% to 53 stocks and tracks the S&P 500 Equal Weight Index Health Care. In terms of industries, healthcare equipment and supplies takes the top spot at roughly 28.5% of the total, closely followed by healthcare providers and services (26.4%) and pharmaceuticals (21.9%).


While large caps account for a substantial 77% of the assets, mid caps take the remainder but for the 2% going to small caps. The product has accumulated $303.8 million in its asset base while it trades in light volume of around 29,000 shares. The expense ratio came in at 0.40%. The fund is down 1.8% over the trailing one-month period.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.


Get the full Report on XLV - FREE

Get the full Report on SPY - FREE

Get the full Report on XHS - FREE

Get the full Report on IHF - FREE

Get the full Report on RYH - FREE


Follow us on Twitter:

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.


Media Contact

Zacks Investment Research

800-767-3771 ext. 9339


Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

Logo -



©2012 PR Newswire. All Rights Reserved.